Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pucotenlimab + chemotherapy + lenvatinib as neoadjuvant therapy for locally advanced head and neck squamous cell carcinoma
ChiCTR2500103869Phase 2Not yet recruiting
- Sponsor
- Department of oncology, Beijing Friendship Hospital, Capital Medical University
- Start
- Jun 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pucotenlimab, lenvatinib, paclitaxel, cisplatin and carboplatin in head and neck squamous cell carcinoma (HNSCC), sponsored by Department of oncology, Beijing Friendship Hospital, Capital Medical University. Primary endpoint: pathological complete response. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
pucotenlimablenvatinibpaclitaxelcisplatincarboplatin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2500103869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103869.